| AstraZeneca Submits Seroquel XR™ in Europe for the Treatment of Major Depressive Disorder
|
(AstraZeneca)
|
10-Jun-2008 |
| Targacept and AstraZeneca Initiate Clinical Trial of AZD3480 in Adult ADHD
|
(Targacept)
|
10-Jun-2008 |
| ONGLYZA(TM) (saxagliptin) Demonstrated Significant Reductions in Key Measures of Glucose Control in Treatment Naive People with Type 2 Diabetes
|
(Bristol-Myers Squibb)
|
07-Jun-2008 |
| Abbott's Phase III Sub-Group Analysis Shows Investigational TriLipix™ in Combination with CRESTOR® Improves Key Lipids in Patients with Mixed Dyslipidemia and Type 2 Diabetes
|
(Abbott Laboratories)
|
07-Jun-2008 |
| ONGLYZA™ (saxagliptin) Demonstrated Significant Reductions in Key Measures of Glucose Control in Treatment Naïve People With Type 2 Diabetes
|
(AstraZeneca)
|
07-Jun-2008 |
| AstraZeneca Submits an sNDA for SYMBICORT® for the Treatment of Asthma in Children as Young as Age Six
|
(AstraZeneca)
|
04-Jun-2008 |
| Phase III study of investigational TRILIPIX™ (SLV348/ABT-335), in combination with AstraZeneca’s CRESTOR® meets primary endpoints on key lipids
|
(Solvay)
|
02-Jun-2008 |
| Watson Receives Final Approval of Omeprazole Delayed-Release Capsules
|
(Watson Pharmaceuticals)
|
02-Jun-2008 |
| Phase III Study of Abbott's Investigational TriLipix(TM) in Combination With AstraZeneca's CRESTOR(R) Meets Primary Endpoints on Key Lipids
|
(Abbott Laboratories)
|
31-May-2008 |
| Infinity Announces Clinical Data Confirming Activity and Safety of IPI-504, a Novel Hsp90 Inhibitor, in Patients With Refractory GIST
|
(Infinity Pharmaceuticals)
|
31-May-2008 |
| AstraZeneca Submits sNDA for NEXIUM® I.V. for Peptic Ulcer Bleed Indication
|
(AstraZeneca)
|
30-May-2008 |
| Cleviprex(TM) Reduces and Controls Acutely Elevated Blood Pressure in Elderly Patients, According to New Analysis from VELOCITY Trial
|
(The Medicines Company)
|
29-May-2008 |
| Study Analyzed SYMBICORT(R) in Children with Persistent Asthma
|
(AstraZeneca)
|
20-May-2008 |
| New Patient Satisfaction Study With budesonide/formoterol Combination Therapy and fluticasone/salmeterol Combination Therapy in Adults With Asthma
|
(AstraZeneca)
|
20-May-2008 |
| POZEN Announces PN 200 Podium Presentation at Digestive Disease Week
|
(POZEN)
|
19-May-2008 |
| Array BioPharma and AstraZeneca Announce New Phase 2 Development Plans for the Investigational Anti-Cancer Drug AZD6244 (ARRY-886)
|
(Array BioPharma)
|
15-May-2008 |
| KV Pharmaceutical Company Announces Approval for the 50 mg Strength of Generic Version of Toprol-XL®
|
(KV Pharmaceutical)
|
15-May-2008 |
| FDA Approves AstraZeneca’s Seroquel for Maintenance Treatment in Bipolar Disorder
|
(AstraZeneca)
|
14-May-2008 |
| Cervarix(TM) Provides Longest Duration of Sustained Neutralising Antibodies Reported for Any Vaccine Against HPV 16 and 18 to Date
|
(GlaxoSmithKline)
|
14-May-2008 |
| AstraZeneca Submits sNDA for Seroquel XR™ for the Treatment of Generalised Anxiety Disorder – a First for the Atypical Antipsychotic Class of Medicines
|
(AstraZeneca)
|
08-May-2008 |
| Novel Therapeutic Agent for Allergic Disorders Discovered in Collaboration with AstraZeneca Progresses to Clinical Development Stage
|
(Dainippon Sumitomo Pharma)
|
08-May-2008 |
| Study Shows Physician Judgment is Important in Reducing Rate of RSV-Related Hospitalizations Among High-Risk Infants
|
(AstraZeneca)
|
05-May-2008 |
| Efficacy of FluMist(R) in Children Highlighted at Pediatric Academic Societies Meeting
|
(AstraZeneca)
|
05-May-2008 |
| New Data on SEROQUEL XR(TM) in Treatment of Both Major Depressive Disorder and Generalized Anxiety Disorder Presented at APA Annual Meeting
|
(AstraZeneca)
|
05-May-2008 |
| Phase 3 Data Regarding Anti-RSV Antibody To Be Presented at Pediatric Academic Societies (PAS) Annual Meeting
|
(AstraZeneca)
|
04-May-2008 |
| AstraZeneca Files Marketing Application in Europe for EGFR Inhibitor Gefitinib (IRESSA™) in Locally Advanced Pre-Treated Non-Small Cell Lung Cancer
|
(AstraZeneca)
|
02-May-2008 |
| AstraZeneca Submits an sNDA for SYMBICORT® for COPD Indication
|
(AstraZeneca)
|
30-Apr-2008 |
| ImClone Announces Agreement with FDA on Special Protocol Assessment for Phase III Study of IMC-1121B in Breast Cancer
|
(ImClone Systems)
|
22-Apr-2008 |
| Human Genome Sciences Completes Enrollment in First of Two Phase 3 LymphoStat-B® Trials
|
(Human Genome Sciences)
|
22-Apr-2008 |
| Mylan Announces Final FDA Approval for Felodipine Extended-Release Tablets, USP
|
(Mylan)
|
21-Apr-2008 |
| MedImmune Advances Asthma Program with Start of a Phase 2 Trial in Europe and Australia and First U.S.-Based Clinical Trial for Antibody Targeting IL-13
|
(AstraZeneca)
|
15-Apr-2008 |
| Preclinical Data Highlighting Potential of Retaspimycin in Treating Non-Small Cell Lung Cancer With Acquired Drug Resistance Presented by Infinity and MedImmune at AACR
|
(AstraZeneca)
|
15-Apr-2008 |
| Shionogi also rides Crestor wave
|
(Shionogi)
|
01-Apr-2008 |
| Statins emerge winners from Vytorin controversy
|
(Schering-Plough)
|
31-Mar-2008 |
| Crestor Outcomes Study JUPITER Closes Early Due to Unequivocal Evidence of Benefit
|
(AstraZeneca)
|
31-Mar-2008 |
| Caraco Pharmaceutical Laboratories Ltd. to Market Generic Ethyol(R)
|
(Caraco Pharmaceutical Laboratories)
|
31-Mar-2008 |
| First Statin Monotherapy to Achieve Regression of Coronary Atherosclerosis by Angiography in a Major Clinical Study
|
(AstraZeneca)
|
31-Mar-2008 |
| Sun Pharmaceutical Announces Launch of Generic Ethyol®
|
(Sun Pharmaceutical Industries)
|
31-Mar-2008 |
| Actavis Bulgaria Launches Record 29 Products in 1Q
|
(Actavis)
|
28-Mar-2008 |
| Supplemental Application for GARDASIL®, Merck's Cervical Cancer Vaccine, Designated Priority Review by the U.S. FDA for Use in Women 27 through 45
|
(Merck & Co)
|
19-Mar-2008 |
| MedImmune Advances Clinical Development of Antibody Targeting Interleukin-9 in Patients with Asthma
|
(AstraZeneca)
|
18-Mar-2008 |
| Study Compares Bronchodilatory Effects of SYMBICORT® and ADVAIR® in Adults with Asthma
|
(AstraZeneca)
|
18-Mar-2008 |
| Genaera Announces MedImmune Initiation of Phase 2a Trial of Antibody Targeting Interleukin-9 in Patients with Asthma
|
(Genaera)
|
18-Mar-2008 |
| Study Analyzed Long-Term SYMBICORT® Use In Children With Persistent Asthma
|
(AstraZeneca)
|
17-Mar-2008 |
| Sun Pharmaceutical Announces USFDA Approval to Market Generic Ethyol®
|
(Sun Pharmaceutical Industries)
|
15-Mar-2008 |
| AstraZeneca Completes Enrollment In Two Pivotal Phase III Studies of The Investigational Drug Vandetanib (ZACTIMA®) In Non-Small Cell Lung Cancer (NSCLC)
|
(AstraZeneca)
|
12-Mar-2008 |
| iCo Therapeutics Provides iCo-008 Phase II Clinical Update
|
(iCo Therapeutics)
|
10-Mar-2008 |
| GlaxoSmithKline Cervical Cancer Vaccine Cervarix® Demonstrates Long Term Protection for More Than Six Years
|
(GlaxoSmithKline)
|
10-Mar-2008 |
| AstraZeneca Submits sNDA for Seroquel XR™ for the Treatment of Major Depressive Disorder
|
(AstraZeneca)
|
29-Feb-2008 |
| FDA Approves NEXIUM® For the Treatment of Short-Term GERD in Children 1 to 11 Years Old
|
(AstraZeneca)
|
28-Feb-2008 |
| AstraZeneca Provides Update On RECENTIN™ Clinical Development Programme
|
(AstraZeneca)
|
27-Feb-2008 |
| Phase II Study of IMC-1121B for Advanced Liver Cancer Commences Patient Enrollment
|
(ImClone Systems)
|
22-Feb-2008 |
| Novacea's Proof-of-Principle Study of AQ4N in Solid Tumors Published in Clinical Cancer Research
|
(Novacea)
|
15-Feb-2008 |
| Bentley Pharmaceuticals Announces Product Approvals in Europe
|
(Bentley Pharmaceuticals)
|
13-Feb-2008 |
| First Head to Head Study Comparing CRESTOR™ and LIPITOR® Effects on the Treatment of Atherosclerosis
|
(AstraZeneca)
|
11-Feb-2008 |
| AstraZeneca Submits Seroquel XR™ in Europe for the Treatment of Bipolar Mania and Bipolar Depression and Seroquel® for Treatment of Bipolar Depression
|
(AstraZeneca)
|
11-Feb-2008 |
| AstraZeneca slides as generic clouds gather
|
(AstraZeneca)
|
07-Feb-2008 |
| Ranbaxy Receives Tentative Approval to Manufacture and Market Esomeprazole Magnesium DR Capsules in USA
|
(Ranbaxy Laboratories)
|
07-Feb-2008 |
| Infinity and MedImmune Announce Approval for Generic Name for Novel Hsp90 Inhibitor
|
(AstraZeneca)
|
04-Feb-2008 |
| MedImmune Submits Biologics License Application to FDA for Motavizumab
|
(AstraZeneca)
|
04-Feb-2008 |
| CytoFab™ Phase 2 Programme in Severe Sepsis Commenced by AstraZeneca
|
(Protherics)
|
22-Jan-2008 |
| First Head to Head Study Comparing CRESTOR™ and LIPITOR® Effects on the Treatment of Atherosclerosis
|
(AstraZeneca)
|
15-Jan-2008 |
| Infinity and MedImmune Initiate Phase 1b Trial of IPI-504 in Combination with Taxotere® in Patients with Advanced Solid Tumor Cancers
|
(AstraZeneca)
|
04-Jan-2008 |
| AstraZeneca Submits sNDAs for Seroquel XR™ for the Treatment of Bipolar Mania and Bipolar Depression
|
(AstraZeneca)
|
02-Jan-2008 |
| Array drug fails, but all may not be lost
|
(Array BioPharma)
|
20-Dec-2007 |
| Human Genome Sciences Initiates Second Randomized Phase 2 Trial of HGS-ETR 1 in Combination With Chemotherapy
|
(Human Genome Sciences)
|
20-Dec-2007 |
| Topline Results Announced from a Phase 2 Study in Advanced Melanoma of Investigational Anti-Cancer Drug AZD6244 (ARRY-886)
|
(Array BioPharma)
|
19-Dec-2007 |
| Infinity and MedImmune Initiate Phase 2 Trial of IPI-504 to Assess the Hsp90 Inhibitor's Potential Anti-Tumor Activity in Patients With Advanced Non-Small Cell Lung Cancer
|
(Infinity Pharmaceuticals)
|
19-Dec-2007 |
| Infinity and Medimmune Initiate Phase 2 Trial of IPI-504 to Assess the Hsp90 Inhibitor’s Potential Anti-Tumor Activity in Patients with Advanced Non-Small Cell Lung Cancer
|
(AstraZeneca)
|
19-Dec-2007 |
| New Approach to Treating Anthrax Significantly Improves Survival Rates in Pivotal Efficacy Studies
|
(Human Genome Sciences)
|
18-Dec-2007 |
| GlaxoSmithKline Receives FDA ‘Complete Response’ Letter for Cervical Cancer Vaccine
|
(GlaxoSmithKline)
|
17-Dec-2007 |
| Data Show ARIMIDEX® (anastrozole) Continues to be Superior to Tamoxifen in Helping Reduce the Risk of Recurrence in Patients With Early Breast Cancer
|
(AstraZeneca)
|
14-Dec-2007 |
| Phase II Study of IMC-1121B for Advanced Malignant Melanoma Commences Patient Enrollment
|
(ImClone Systems)
|
13-Dec-2007 |
| Perrigo Announces Final FDA Approval of Dexcel's OTC Omeprazole
|
(Perrigo)
|
10-Dec-2007 |
| FDA Concludes There is No Increased Risk of Cardiac Events For Patients Treated with Omeprazole and NEXIUM® (Esomeprazole Magnesium)
|
(AstraZeneca)
|
10-Dec-2007 |
| Micromet and MedImmune Present New Clinical Data for MT103 at the American Society of Hematology Annual Meeting Suggesting Potent Single-Agent Activity in Patients with Relapsed Mantle Cell and Follicular Lymphoma
|
(AstraZeneca)
|
10-Dec-2007 |
| AstraZeneca Presents its Global Biologics Organisation, MedImmune, at 2007 Analyst and Investor R&D Day
|
(AstraZeneca)
|
07-Dec-2007 |
| AstraZeneca Presents New Depression and Anxiety Results for SEROQUEL XR™
|
(AstraZeneca)
|
05-Dec-2007 |
| AstraZeneca Completes Enrollment in First Phase III Study of the Investigational Drug Vandetanib (ZACTIMA)(R) in Non-Small Cell Lung Cancer
|
(AstraZeneca)
|
30-Nov-2007 |
| MedImmune Initiates First Clinical Trial of Monoclonal Antibody Targeting GM-CSFR in Patients with Rheumatoid Arthritis
|
(AstraZeneca)
|
26-Nov-2007 |
| Seroquel XR™ Receives Approval from FDA for Maintenance Treatment of Schizophrenia
|
(AstraZeneca)
|
16-Nov-2007 |
| The New England Journal of Medicine Publishes First Clinical Results for MedImmune's Chitinase-like Protein YKL-40 in Patients With Asthma
|
(AstraZeneca)
|
14-Nov-2007 |
| Infinity and MedImmune Initiate Phase 2 Clinical Trial of IPI-504, a Novel HSP90 Inhibitor, in Patients with Advanced Hormone-Refractory Prostate Cancer
|
(AstraZeneca)
|
13-Nov-2007 |
| Infinity and MedImmune Initiate Phase 2 Clinical Trial of IPI-504, a Novel Hsp90 Inhibitor, in Patients With Advanced Hormone-Refractory Prostate Cancer
|
(Infinity Pharmaceuticals)
|
13-Nov-2007 |
| CRESTOR® Now Indicated to Slow the Progression of Atherosclerosis in Patients with Elevated Cholesterol
|
(AstraZeneca)
|
09-Nov-2007 |
| MedImmune Presents Data from Its Advancing Inflammatory Disease Portfolio at 71st Annual Meeting of The American College of Rheumatology
|
(AstraZeneca)
|
08-Nov-2007 |
| New Analysis of METEOR Study Demonstrate Effects of AstraZeneca's CRESTOR(R) (Rosuvastatin Calcium) on Atherosclerosis in Patients with Two or More Risk Factors for Cardiovascular Disease
|
(AstraZeneca)
|
07-Nov-2007 |
| New Data Examines the Effect of Adding a Statin to Optimised Treatment for Patients With Advanced Heart Failure
|
(AstraZeneca)
|
05-Nov-2007 |
| New Data Presented on GARDASIL(R), Merck's Cervical Cancer Vaccine, in Women Through Age 45
|
(Merck & Co)
|
04-Nov-2007 |
| CRESTOR™ ANDA
|
(AstraZeneca)
|
01-Nov-2007 |
| Infinity and MedImmune Present Preliminary Phase 1 Data Demonstrating Biological Activity of IPI-504, A Novel Hsp90 Inhibitor, in Advanced Non-Small Cell Lung Cancer
|
(Infinity Pharmaceuticals)
|
25-Oct-2007 |
| Human Genome Sciences Presents New Data Showing Anti-tumor Activity and Safety of Trail Receptor Antibodies in Combination With Chemotherapy
|
(Human Genome Sciences)
|
24-Oct-2007 |
| Infinity and MedImmune Announce Issuance of U.S. Patent for Proprietary Heat Shock Protein 90 Inhibitors
|
(Infinity Pharmaceuticals)
|
23-Oct-2007 |
| Ranbaxy Receives Approval to Market Ran®-Lisinopril in Canada
|
(Ranbaxy Laboratories)
|
22-Oct-2007 |
| Cervical Cancer Vaccine Available in the UK
|
(Merck & Co)
|
17-Oct-2007 |
| First Vaccine That Can Prevent Cervical Cancer, Genital Warts and Other Human Papillomavirus Diseases Is Now Available in the UK
|
(Sanofi Pasteur MSD)
|
17-Oct-2007 |
| Studies Show Body Mass Index Has No Effect on Resolution and Healing of GERD Symptoms
|
(AstraZeneca)
|
16-Oct-2007 |
| Novacea Initiates Phase 2 Trial of AQ4N in Acute Lymphoblastic Leukemia
|
(Novacea)
|
11-Oct-2007 |
| New Research Further Supports Cervarix(TM) in Protecting Against Cervical Cancer
|
(GlaxoSmithKline)
|
05-Oct-2007 |
| GSK Seeks Prequalification for Cervarix™ from the World Health Organization After Obtaining Marketing Approval in Europe
|
(GlaxoSmithKline)
|
04-Oct-2007 |
| GSK Submits Cervarix(TM) Licence Application to Japan’s Health Authorities
|
(GlaxoSmithKline)
|
28-Sep-2007 |
| Survival Data Presented From Phase II Study of Investigational Drug ZD4054 in Hormone Resistant Prostate Cancer Patients
|
(AstraZeneca)
|
25-Sep-2007 |
| Cervarix(TM), GSK’S Cervical Cancer Vaccine, Approved in Europe
|
(GlaxoSmithKline)
|
24-Sep-2007 |
| FDA Approves Expanded Label for FluMist(R) to Include Children Two to Five Years of Age
|
(AstraZeneca)
|
19-Sep-2007 |
| GlaxoSmithKline Extends Long-term Cervical Cancer Vaccine Clinical Trial for Three Additional Years
|
(GlaxoSmithKline)
|
19-Sep-2007 |
| Infinity and MedImmune Receive Orphan Drug Designation for IPI-504 for Treatment of Gastroinstestinal Stromal Tumors
|
(Infinity Pharmaceuticals)
|
17-Sep-2007 |
| Infinity and MedImmune Receive Orphan Drug Designation for IPI-504 for Treatment of Gastroinstestinal Stromal Tumors
|
(AstraZeneca)
|
17-Sep-2007 |
| Actavis Launches Prostate Cancer Drug Bicalutamide in Norway
|
(Actavis)
|
13-Sep-2007 |
| AstraZeneca and Pozen to Start Phase III Trials with PN400
|
(AstraZeneca)
|
07-Sep-2007 |
| POZEN/AstraZeneca Announce Start of the PN 400 Phase III Program
|
(POZEN)
|
07-Sep-2007 |
| Study Shows IRESSA™ (Gefitinib) is as Effective as Docetaxel in Pre-Treated Advanced NSCLC
|
(AstraZeneca)
|
05-Sep-2007 |
| AstraZeneca and Abbott Announce Selection of Next-Generation Fenofibrate (ABT-335) and CRESTOR® Fixed-Dose Combination
|
(AstraZeneca)
|
31-Aug-2007 |
| Abbott and AstraZeneca Announce Selection of Next-Generation Fenofibrate ABT-335 and CRESTOR® Fixed-Dose Combination
|
(Abbott Laboratories)
|
31-Aug-2007 |
| AstraZeneca’s Once-Daily SEROQUEL XR™ Extended-Release Tablets Approved in Netherlands For The Acute and Long Term Treatment of Schizophrenia
|
(AstraZeneca)
|
29-Aug-2007 |
| Approval of an Additional Dosage and Administration for Secondary Eradication of Helicobacter Pylori for Proton Pump Inhibitors in Japan
|
(Eisai)
|
24-Aug-2007 |
| Targacept Announces Initiation of Phase IIb Development of AZD3480 (TC-1734) for Cognitive Deficits in Schizophrenia
|
(Targacept)
|
23-Aug-2007 |
| MedImmune's Motavizumab Reduced RSV Hospitalizations by 83 Percent Among Study
|
(AstraZeneca)
|
23-Aug-2007 |
| APP Receives Expedited Approval for the First and Only Generic Cefotetan Disodium for Injection
|
(APP Pharmaceuticals)
|
10-Aug-2007 |
| Phase II Study of IMC-11F8 for Advanced Colorectal Cancer Has Commenced Patient Enrollment in Europe
|
(ImClone Systems)
|
09-Aug-2007 |
| Par Pharmaceutical Begins Shipment of Additional Dosage Strength of Generic TOPROL-XL®
|
(Par Pharmaceutical)
|
03-Aug-2007 |
| MedImmune Initiates Phase 2a Multi-Dose Study in Patients with Asthma
|
(AstraZeneca)
|
01-Aug-2007 |
| Par Pharmaceutical Begins Shipment of Additional Dosage Strengths of Generic TOPROL-XL®
|
(Par Pharmaceutical)
|
26-Jul-2007 |
| KV Pharmaceutical Announces Launch of Two Strengths of Generic Versions of Toprol-XL®
|
(KV Pharmaceutical)
|
26-Jul-2007 |
| MedImmune Announces Interim Phase 1 Study Results for Potential Asthma Therapy
|
(AstraZeneca)
|
23-Jul-2007 |
| Targacept Announces Initiation of Phase IIb Development of AZD3480 (TC-1734) for Alzheimer’s Disease
|
(Targacept)
|
23-Jul-2007 |
| Medarex Announces Advancement of Antibody Development by Partner
|
(Medarex)
|
19-Jul-2007 |
| MedImmune Advances Potential Treatment for Patients With Lupus
|
(AstraZeneca)
|
19-Jul-2007 |
| GSK’S Cervical Cancer Candidate Vaccine Cervarix™ Receives Positive Opinion in Europe for Prevention of Cervical Cancer
|
(GlaxoSmithKline)
|
18-Jul-2007 |
| RSV Drug Starts Phase Ia Clinical Trials
|
(Biota)
|
17-Jul-2007 |
| RSV Drug Starts Phase Ia Clinical Trials
|
(AstraZeneca)
|
16-Jul-2007 |
| Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Tenormin(R)
|
(Caraco Pharmaceutical Laboratories)
|
11-Jul-2007 |
| Silence Therapeutics signs siRNA Research & Development Collaboration with AstraZeneca to Develop Novel Respiratory Therapeutics
|
(Silence Therapeutics)
|
06-Jul-2007 |
| MedImmune Begins Dosing Children Six Months to 24 Months of Age in Phase 1 Study of Vaccine to Help Prevent Two of the Most Common Viral Causes of Childhood Respiratory Illness
|
(AstraZeneca)
|
03-Jul-2007 |
| Lupin Gets MHRA Approval for Lisinopril in UK
|
(Lupin)
|
02-Jul-2007 |
| New Study in Journal of Pediatrics Suggests Synagis® (palivizumab) May Reduce Subsequent Recurrent Wheezing in Preterm Infants
|
(Abbott Laboratories)
|
29-Jun-2007 |
| New Study in Journal of Pediatrics Suggests Synagis(R) (Palivizumab) May Reduce Subsequent Recurrent Wheezing in Preterm Infants
|
(AstraZeneca)
|
29-Jun-2007 |
| Largest Cervical Cancer Vaccine Efficacy Trial Shows Cervarix™ Provides Excellent Protection Against Lesions Caused by Most Common Cancer-Causing Virus Types
|
(GlaxoSmithKline)
|
27-Jun-2007 |
| Data Demonstrated Saxagliptin Added to Metformin Improved Glycemic Control in Subjects with Type 2 Diabetes Compared to Metformin Alone
|
(Bristol-Myers Squibb)
|
25-Jun-2007 |
| AstraZeneca Announces Symbicort® is Now Available in the U.S.
|
(AstraZeneca)
|
25-Jun-2007 |
| First Phase II Short-Term Study on Dapagliflozin Shows Results on Safety, Tolerability and Glycemic Markers in Subjects with Type 2 Diabetes
|
(Bristol-Myers Squibb)
|
25-Jun-2007 |
| Data Demonstrated Saxagliptin Added to Metformin Improved Glycemic Control in Subjects with Type 2 Diabetes Compared to Metformin Alone
|
(AstraZeneca)
|
25-Jun-2007 |
| First Phase II Short-Term Study on Dapagliflozin Shows Results on Safety, Tolerability and Glycemic Markers in Subjects with Type 2 Diabetes
|
(AstraZeneca)
|
25-Jun-2007 |
| Merck Provides Update on Status of Supplemental Biologics License Applications (sBLA) for GARDASIL(R)
|
(Merck & Co)
|
20-Jun-2007 |
| Perrigo Announces Tentative FDA Approval of Dexcel's OTC Omeprazole
|
(Perrigo)
|
20-Jun-2007 |
| Myriad Genetics Collaborates With AstraZeneca on Phase 2 Trials
|
(Myriad Genetics)
|
19-Jun-2007 |
| Human Genome Sciences Reports that a Phase 2 Study of Lymphostat-b® Showed Significant Reductions in Disease Activity in Patients with Active Systemic Lupus Erythematosus
|
(Human Genome Sciences)
|
14-Jun-2007 |
